3929 Point Eden Way
16 articles with Eikon Therapeutics
Eikon Therapeutics Announces Long-Term Lease with Alexandria Real Estate Equities, Inc. for New Corporate Headquarters in the San Francisco Bay Area
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters.
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors.
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
Eikon Therapeutics Inc. today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022.
3/25/2022Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer
Eikon Therapeutics, Inc. today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022.
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team
Eikon is employing super-resolution microscopy and advanced engineering to invent novel medicines that improve and extend life.
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
7/2/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Eikon Therapeutics, Inc. today announced that it has named Alfred “Freddie” Bowie, Jr, PhD, to the newly created position of Chief Financial Officer.
Eikon Therapeutics Closes $148 Million Series A Financing to Develop High-Throughput, Super-Resolution Microscopy for Drug Discovery
Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital.
Roger Perlmutter, the former president of Merck Research Laboratories, will helm drug discovery startup Eikon Therapeutics, Inc.